| Literature DB >> 20576297 |
Olga Barca1, Pablo Devesa-Peleteiro, Marcos Seoane, Rosa M A Señarís, Víctor M Arce.
Abstract
Accumulating evidence indicates that interferon-β (IFN-β) can modify the complex immunopathogenic scenario causing clinical relapse activity and disease progression in MS. However, the beneficial effects of IFN-β in MS patients may also depend on non-immune mechanisms, including the modulation of astrocyte function. In the present report, we have shown that, depending on the dose, IFN-β treatment can either promote astrocyte proliferation and survival, or result astrocyte death. These actions depend, at least in part, on the regulation of nuclear factor-kappa B (NF-κB), an inducible transcription factor present in neurons and glia. This bimodal effect of IFN-β adds a new layer of complexity in the actions of IFN-β within the CNS.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20576297 DOI: 10.1016/j.jneuroim.2010.05.036
Source DB: PubMed Journal: J Neuroimmunol ISSN: 0165-5728 Impact factor: 3.478